CJC-1295 With DAC vs Without DAC: Half-Life and Research Design
Drug Affinity Complex (DAC) extends half-life of GHRH analogs. What that means for dosing frequency in animal studies versus no-DAC variants—conceptual overview only.
Background
Native GHRH has a circulating half-life of ~7 minutes, dominated by DPP-4-mediated cleavage at the N-terminus. CJC-1295 (no DAC), with four amino-acid substitutions, extends this to ~30 minutes. The DAC (Drug Affinity Complex) modification takes that further — to 6–8 days — fundamentally changing the pharmacodynamics and what the molecule is useful for in research.
What DAC is, chemically
DAC is a maleimidopropionic acid (MPA) linker conjugated to the C-terminus of modified GRF(1-29). The maleimide group forms a covalent thioether bond with a reactive cysteine residue on serum albumin (Cys-34 on human albumin). Key consequences:
- CJC-1295 becomes covalently tethered to albumin shortly after administration
- Albumin's half-life (~19 days in humans) becomes the rate-limiting factor for CJC-1295 clearance
- Circulating CJC-1295-DAC concentration remains relatively stable over days rather than oscillating with each injection
Pharmacodynamic consequence
The biological difference is not just longer — it's qualitatively different:
CJC-1295 no-DAC produces a pulsatile GH response similar to endogenous GHRH:
- Sharp GH peak within minutes of administration
- Return to baseline within 1–2 hours
- Preserves normal pulsatile rhythm that is thought to underpin physiological IGF-1 generation
CJC-1295 with DAC produces a sustained GH/IGF-1 elevation:
- GH pulse amplitude preserved but baseline GH elevated
- IGF-1 remains elevated continuously for days
- Loss of pulsatility — receptor desensitization dynamics differ from physiological state
Pulsatility matters. Some research suggests continuous GH exposure drives different hepatic gene expression patterns than pulsatile exposure (e.g., sex-specific cytochrome P450 induction in rodents). Study design should consider whether sustained or pulsatile stimulation better matches the endpoint.
Research design implications
Use no-DAC when:
- You need physiological pulse dynamics
- Acute receptor engagement is the endpoint
- You're pairing with GHRPs in combination studies (pulsatility matters for synergy)
- You need frequent dosing control over concentration-time profile
Use DAC when:
- You want to test sustained IGF-1 elevation as the independent variable
- The study is long-duration (weeks) and frequent injections would confound results
- You're investigating chronic GH/IGF-1 exposure phenotypes
- You need stable plasma concentration without frequent intervention
What the literature shows
- PK studies in rats demonstrate ~8-day effective GH stimulation after a single DAC-CJC administration
- IGF-1 elevation is dose-dependent but plateaus at a dose-dependent ceiling
- Tachyphylaxis (reduced GH response) emerges faster with DAC than no-DAC in chronic administration models
- Receptor downregulation kinetics differ substantially between the two
Handling notes — no differences
From a handling standpoint, both variants are treated identically:
- Lyophilized powder; store at -20°C light-protected
- Reconstitute with sterile/bacteriostatic water
- Stability ~4 weeks at 2–8°C reconstituted
- HPLC purity ≥99.0%; MS identity; batch-specific COA
The DAC linker is stable under these conditions.
Related reading
- /research/cjc-1295-no-dac — no-DAC compound profile
- /compare/cjc-1295-dac-vs-no-dac — direct comparison
- /blog/sermorelin-vs-cjc-1295-ghrh-analog-research — GHRH-class comparison
- /blog/cjc-1295-ipamorelin-mechanism — combination pharmacology
- /category/muscle-growth-research — broader category
RUO disclaimer
For laboratory research use only. Not for human consumption. We do not provide dosing schedules — consult published literature and institutional oversight for study design.